Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
Tocilizumab is a monoclonal antibody directed against the interleukin-6 receptor. It has been proposed to mitigate the cytokine storm syndrome associated with severe COVID-19. In this observational study, patients with the syndrome who received tocilizumab had reduced mortality.

Related Post